Department of Gastrointestinal Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
College of Science and Technology, China Three Gorges University, Yichang, China.
Bioengineered. 2021 Dec;12(2):9779-9789. doi: 10.1080/21655979.2021.1995104.
Gastric cancer (GC) is one of the most common and lethal cancers worldwide. The Nudix hydroxylase (NUDT) genes have been reported to play notable roles in tumor progression. However, the role of NUDT10 in GC has not been reported. In this study, we investigated the expression of NUDT10 in GC and its association with clinicopathological characteristics. Quantitative real-time polymerase chain reaction and analyses of The Cancer Genome Atlas and Human Protein Atlas databases were performed to determine NUDT10 mRNA and protein expression. Receiver operating characteristic curve analysis was used to assess the diagnostic value of NUDT10 in patients with GC. We used Cox regression and the Kaplan-Meier method to assess the correlations between clinicopathological factors and survival outcomes of patients with GC. Gene set enrichment analysis (GSEA) was performed to identify the underlying signaling pathways. NUDT10 mRNA and protein expression was significantly lower in GC tissues compared to normal tissues. Interestingly, higher NUDT10 expression was correlated with advanced tumor stage, deeper local invasion, and worse survival outcomes. Patients with higher NUDT10 expression had a significantly worse prognosis than those with lower NUDT10 expression. Multivariate analysis showed that high NUDT10 expression was an independent predictor of survival outcome. Several pathways, including mismatch repair, nucleotide excision repair, extracellular matrix receptor interaction, and cancer signaling, were identified as enriched pathways in GC through GSEA. To our knowledge, this study is the first to characterize NUDT10 expression in GC. Our study demonstrates that NUDT10 is a promising independent biomarker for GC prognosis.
胃癌（GC）是全球最常见和最致命的癌症之一。Nudix 水解酶（NUDT）基因已被报道在肿瘤进展中发挥显著作用。然而，NUDT10 在 GC 中的作用尚未报道。在本研究中，我们研究了 NUDT10 在 GC 中的表达及其与临床病理特征的关系。通过定量实时聚合酶链反应和分析癌症基因组图谱和人类蛋白质图谱数据库来确定 NUDT10 mRNA 和蛋白质表达。使用接收者操作特征曲线分析评估 NUDT10 在 GC 患者中的诊断价值。我们使用 Cox 回归和 Kaplan-Meier 方法评估 GC 患者临床病理因素与生存结局的相关性。进行基因集富集分析（GSEA）以鉴定潜在的信号通路。与正常组织相比，GC 组织中 NUDT10 mRNA 和蛋白质表达显著降低。有趣的是，较高的 NUDT10 表达与较晚期的肿瘤分期、较深的局部浸润和较差的生存结局相关。NUDT10 表达较高的患者预后明显比 NUDT10 表达较低的患者差。多变量分析表明，高 NUDT10 表达是生存结局的独立预测因子。通过 GSEA，鉴定出几个通路，包括错配修复、核苷酸切除修复、细胞外基质受体相互作用和癌症信号通路，这些通路在 GC 中富集。据我们所知，这项研究首次对 GC 中的 NUDT10 表达进行了描述。我们的研究表明，NUDT10 是 GC 预后的一个有前途的独立生物标志物。
